Skip to content

A study to learn how much elinzanetant gets into the blood, how safe it is and how it affects the body after taking single and multiple amounts in healthy subjects

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2023-503864-17-00
Acronym
22382
Enrollment
36
Registered
2023-08-08
Start date
2023-09-20
Completion date
2024-02-23
Last updated
2023-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vasomotor Symptoms as a sex hormone-dependent disorder in women and men

Interventions

None listed

Sponsors

Bayer Consumer Care AG, Bayer Consumer Care AG, Bayer AG
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to 64 Years

Countries

Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026